Hester Biosciences Limited has informed the Exchange regarding Appointment of Ms. Priya Gandhi as Executive Director of the company w.e.f. October 28, 2026.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences reported strong FY26 results with standalone profit after tax of INR 521 million, up 64% from INR 318.42 million in FY25. Consolidated profit after tax nearly doubled to INR 574.84 million from INR 288.26 million. Standalone revenue from operations was INR 2,921.36 million vs INR 2,864.66 million in FY25. The Board recommended a dividend of INR 11 per share (110%) for FY26, subject to shareholder approval. The company also completed divestment of its Texas Lifesciences Private Limited subsidiary in March 2026. Ms. Priya Gandhi, daughter of CEO Rajiv Gandhi, has been re-appointed as Executive Director for 3 years effective October 28, 2026.
The significant improvement in profitability and shareholder returns through dividend is positive for investors. The re-appointment of a promoter family member to the board maintains continuity in governance.